Format

Send to

Choose Destination
Cancer Cell. 2012 Oct 16;22(4):452-65. doi: 10.1016/j.ccr.2012.09.016.

Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.

Author information

1
Department of Pathology and Howard Hughes Medical Institute, New York University School of Medicine, New York, NY 10016, USA.

Abstract

D-type cyclins form complexes with cyclin-dependent kinases (CDK4/6) and promote cell cycle progression. Although cyclin D functions appear largely tissue specific, we demonstrate that cyclin D3 has unique functions in lymphocyte development and cannot be replaced by cyclin D2, which is also expressed during blood differentiation. We show that only combined deletion of p27(Kip1) and retinoblastoma tumor suppressor (Rb) is sufficient to rescue the development of Ccnd3(-/-) thymocytes. Furthermore, we show that a small molecule targeting the kinase function of cyclin D3:CDK4/6 inhibits both cell cycle entry in human T cell acute lymphoblastic leukemia (T-ALL) and disease progression in animal models of T-ALL. These studies identify unique functions for cyclin D3:CDK4/6 complexes and suggest potential therapeutic protocols for this devastating blood tumor.

PMID:
23079656
PMCID:
PMC3493168
DOI:
10.1016/j.ccr.2012.09.016
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Secondary source ID, Grant support

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center